Eli Lilly on Thursday released new data showing strong results for a widely anticipated obesity treatment.
Adults with obesity or overweight and type 2 diabetes who took tirzepatide during a late-stage clinical trial lost up to 15.7% of their body weight, or about 34.4 pounds, Lilly LLY said. More than 80% of people taking tirzepatide lost at least 5% of their body weight, the company said, compared with about 30% of those taking a placebo.
This article was originally published by Marketwatch.com. Read the original article here.